What CDSCO Approval Actually Means

"CDSCO approved" turns up on packaging, in news copy and in arguments on the internet, and it does far less work than most readers assume.

A CDSCO approval is a central authorisation that a specific product, in a specific form and strength, may be marketed in India for a specific stated use, subject to whatever conditions the regulator attached. It does not certify that a medicine is safe for any particular person, does not rank it against other medicines, and does not permit advertising it. Below is what the decision covers, who makes it, and what a person can and cannot check as of 2026.

Key Takeaways:

• CDSCO is the central drug authority under the Drugs and Cosmetics Act 1940. It approves new drugs and controls imported drug quality. State Drug Licensing Authorities separately issue manufacture and sale licences.
• An approval authorises a claim, not a chemical. A different indication is a separate application with its own data package. Semaglutide holds two separate authorisations in India: one for type 2 diabetes and one for chronic weight management.
• Obesity is listed in the Schedule of the Drugs and Magic Remedies (Objectionable Advertisements) Act 1954. A CDSCO approval does not displace that advertising prohibition.
• Approval does not close the file. Phase IV studies, pharmacovigilance commitments and adverse event reporting may be required. CDSCO may prohibit under section 26A where a drug's use involves risk.
• Generic applicants face the same approval pathway. A patent expiry changes who may apply, not the requirement for bioequivalence data and central permission.

Two different authorities are involved in getting any medicine onto an Indian shelf, and confusing them is the source of most misreadings. The Central Drugs Standard Control Organisation, operating under the Directorate General of Health Services in the Ministry of Health and Family Welfare, is the central drug authority under the Drugs and Cosmetics Act 1940. It is headed by the Drugs Controller General (India), who acts as the Central Licensing Authority and is responsible for approving new drugs, permitting clinical trials, and controlling the quality of imported drugs.

Manufacture, sale and distribution are primarily a state concern. State Drug Licensing Authorities issue the licences that let a factory manufacture for sale and let a shop sell wholesale or retail, under provisions including Rules 61 to 65 of the Drugs and Cosmetics Rules, 1945. A central approval and a pharmacy's licence to sell are separate decisions, taken by different authorities.

CDSCO does not decide alone. Three bodies are involved in the central assessment:

• The Drugs Technical Advisory Board, constituted under section 5 of the Act, advises central and state governments on technical matters.
• Subject Expert Committees of external specialists review individual applications and recommend whether permission should be granted.
• Committee minutes, where published, record the view taken on trial design, safety, efficacy and the risk-benefit balance.

The pathway sits in the New Drugs and Clinical Trials Rules 2019, notified as G.S.R. 227(E) and gazetted on 19 March 2019 under sections 12 and 33 of the Drugs and Cosmetics Act. An applicant wanting to manufacture or import a new drug for sale applies to the Central Licensing Authority on prescribed forms, submitting chemical and pharmaceutical information, non-clinical data, clinical trial data and the drug's regulatory status in other countries.

Whether Indian trial data is required depends on the drug's history. For a substance discovered in India, local trials are required from Phase I onward. For a drug already approved and marketed in other major countries for the proposed claim, a waiver of some local trials may be considered on expert-committee recommendation, where metabolism is not affected by ethnic differences and the foreign data supports a favourable benefit-risk ratio.

What the DCGI grants at the end is a written permission specifying:

• The approved indication
• Dosage form and strength
• Route of administration
• Target population
• Any special conditions, such as pharmacovigilance commitments or prescriber restrictions

Approval does not close the file. Sponsors may be required to run Phase IV studies and submit periodic safety update reports and serious adverse event reports. Under section 26A, the Central Government may prohibit manufacture, sale or distribution in the public interest where a drug's use is likely to involve risk, or where it lacks the therapeutic value claimed.

Indian law authorises a claim, not a chemical. Rule 122E treats a drug already approved for certain claims as a new drug all over again when it is proposed to be marketed with modified or new claims, naming indications, dosage, dosage form and route of administration. A change of indication is therefore a fresh application with its own data package, its own risk-benefit assessment and its own conditions.

The practical consequence is that one molecule can hold two separate authorisations that share nothing but the active ingredient. Semaglutide is the clearest Indian example: an authorisation covering glycaemic control in type 2 diabetes and a separate authorisation covering chronic weight management in adults with specified medical conditions. Approval for one does not imply approval for the other in either direction.

A March 2026 answer in the Rajya Sabha recorded that three molecules hold obesity or weight-management approvals in India, and that those approvals carry prescriber conditions that the diabetes approvals do not necessarily carry.

Use outside the approved indication is where Indian law becomes genuinely unsettled. Legal analyses argue that a drug may only be sold for indications it has been approved for, so off-label use is prohibited. Academic reviews say the same while noting that CDSCO and the DCGI do not regulate the practice of medicine, which falls to professional-conduct regulation, and that no clear guidelines on off-label use exist.

Off-label marketing and promotion are clearly prohibited. The legality of an individual doctor's off-label prescription is ambiguous, governed mainly by negligence and professional-conduct standards rather than by express statutory permission.

An approval records that, on the data submitted, a product has an acceptable safety, efficacy and quality profile for a stated indication and population. The assessment is population-level. It says nothing about whether a particular person should take the drug, and the Act anticipates that later evidence can change the answer.

Indian approvals do not rank drugs by efficacy or cost-effectiveness. The requirement is a favourable benefit-risk ratio for the intended indication, not superiority over existing therapies, and drugs are routinely approved as alternatives or additions within a class.

Section 3 of the Drugs and Magic Remedies (Objectionable Advertisements) Act 1954 prohibits publishing any advertisement referring to a drug in terms suggesting its use for any condition listed in the Act's Schedule. Obesity is one of those conditions.

Section 14 sets out narrow exemptions:

• Signboards or notices by registered medical practitioners on their own premises.
• Bona fide scientific or social treatises.
• Confidential communications sent only to registered medical practitioners.
• Certain government-printed or government-sanctioned material.

None of those creates a general permission for consumer-facing weight-loss advertising, and a CDSCO approval does not displace the prohibition.

Regulators have applied that position directly. A CDSCO advisory reported in March 2026 directed manufacturers, importers and marketing authorisation holders of GLP-1 receptor agonists to stop misleading advertisements and any promotional activity, including so-called awareness campaigns functioning as surrogate advertisement for prescription drugs. That advisory was not publicly retrievable as a document for this article, so its contents are reported through law-firm and media summaries rather than confirmed against the primary text.

A public notice dated 18 May 2026, directing state and union territory drug controllers to strengthen enforcement against unauthorised promotion and distribution of GLP-1-based drugs, is published on CDSCO's own notices page.

An approval attaches to a product's authorisation, not to any particular batch. Whether a given batch meets quality standards is handled separately, through the monthly Not of Standard Quality alerts and spurious drug alerts that list specific non-compliant batches. Whether a particular seller is lawfully selling it depends on that seller's state licence, which a central approval says nothing about.

Three public sources answer three different questions, and none of them answers all three:

• Confirm the product is centrally authorised: CDSCO publishes a List of Approved New Drugs as annual PDFs. Entries typically carry the drug name, dosage form, strength, indication and date of approval.
• Check whether the batch has been flagged: CDSCO's alerts pages carry monthly Not of Standard Quality lists and spurious drug lists by product and batch number. Reading the current alerts against the batch printed on a pack is the only public check available at batch level.
• Read the pack against what the Rules require: Under Rules 96 and 97, the innermost container and every outer covering must carry the generic name, brand name, manufacturer's name and address, batch number, manufacturing and expiry dates and, where applicable, licence numbers. Amendments notified in 2018 require Schedule G, H, H1 and X drugs to display their caution text in black inside a completely red rectangular box, with the Rx, NRx or XRx symbol in red at the top-left corner.

A pack missing those particulars, or a batch appearing on an alert list, is a reason to stop and raise it with the pharmacist and the prescriber.

Schedule H lists the drugs that may not be sold by retail except on, and in accordance with, the prescription of a registered medical practitioner. The obligations that follow fall on the seller.

Rule 65 requires the supply of a Schedule H drug against a prescription to be entered in a prescription register at the time of supply, recording the date, a serial number, the prescriber's name and address, the patient's name, the drug and the quantity, and for Schedule C, H and H1 substances also the manufacturer's name, batch number and expiry date. Schedule H1, a stricter subset, goes further: Rule 65(11) requires supplies to be recorded in a separate register retained for three years and open to inspection.

Sale offences under the Act attach to the retailer. A pharmacy dispensing a Schedule H drug without a valid prescription, or failing to keep the prescribed registers, faces prosecution and possible suspension or cancellation of its licence. Where an approval carries a prescriber restriction, the pharmacy is also expected to check that the prescriber falls within the permitted category.

Novo Nordisk's Indian composition patent on semaglutide expired on 20 March 2026, a date consistently cited across independent reporting and patent-office analyses, though the patent documents themselves were not retrieved for this article. Litigation over intellectual property covering the oral form has continued past that date, so the position is not uniform across every formulation.

What expiry changes is who may apply. What it does not change is the pathway. A generic is treated as a new drug for the subsequent applicant and requires demonstrated bioequivalence to the reference product before marketing authorisation. Central permission still comes first, and state manufacturing licences still follow it.

Conditions are expected to travel with the authorisation rather than lapse with the patent, because a generic is authorised for the specific approved claim rather than for the molecule at large.

An approval is a permission with its boundaries written into it: this product, this form, this strength, this indication, this population, these conditions. Everything a reader might want it to mean beyond that: that a medicine is right for them, that it is the best option available, that the pack in their hand is genuine, that the seller is licensed, sits outside the decision.

The useful habit is asking which authority answered which question, and noticing when nobody has.

Questions about whether a specific approved medicine is appropriate for you? A Voy clinician can read your situation against the approval conditions that apply. Book a consultation.

This article is for general information and education only and is not medical advice, diagnosis, or treatment. GLP-1 and other medications referenced are prescription-only and are appropriate only for certain people under the supervision of a qualified clinician. Do not start, stop, or change any medication based on this article. Please consult a registered medical practitioner about your individual circumstances. Information reflects what was available at the time of review and may change.